Luminopia visual acuity gains maintained after treatment in children with amblyopia
Children with amblyopia maintained visual acuity gains after completing treatment with Luminopia, according to real-world data from the PUPiL Registry presented at Academy 2026 Anaheim.
The analysis included 84 children between the ages of 4 and 13 years with unilateral anisometropic, strabismic, or mixed amblyopia. Patients completed an average of 131 hours of treatment over 8.3 months. Mean best-corrected visual acuity (BCVA) improved by 1.3 lines at the end of treatment. Similar improvements were noted among children aged ≤7 years and those aged ≥8 years.
Best-corrected visual acuity was maintained at 6.7 months after treatment, with a mean change of +0.1 lines from the end of treatment. The findings met the prespecified 1-line non-inferiority margin (P < 0.001). Recurrence, defined as a loss of at least 2 lines of BCVA, occurred in 3.6% of patients.
In 27 children followed for 8 to 12 months after treatment, BCVA changed by +0.3 lines from the end of treatment, meeting the prespecified non-inferiority margin (P < 0.001). Recurrence occurred in 3.7% of this group. No serious adverse events were reported.
Reference
Williamson A, et al. Visual Acuity Gains Maintained Following Dichoptic Treatment in Children with Unilateral Amblyopia in Clinical Practice. Presented at: American Academy of Optometry (Academy 2026); September 30-October 3, 2026; Anaheim, CA.
Related Content
